Stay updated on Durvalumab Combo in Newly Diagnosed Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Combo in Newly Diagnosed Multiple Myeloma Clinical Trial page.

Latest updates to the Durvalumab Combo in Newly Diagnosed Multiple Myeloma Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has removed extensive details about a clinical study for durvalumab in combination with lenalidomide for multiple myeloma, including the study's design, dosing information, and FDA hold status. It has added a new version number and references to the study's identifiers.SummaryDifference34%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.5%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference0.5%
Stay in the know with updates to Durvalumab Combo in Newly Diagnosed Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Combo in Newly Diagnosed Multiple Myeloma Clinical Trial page.